Healthcare Equipment and Supplies
Company Overview of Biocare Medical, LLC
Biocare Medical, LLC develops and supplies automated immunohistochemistry instrumentation and a range of reagents for IHC lab testing. It offers a portfolio of integrated tissue diagnostic products for cancer and infectious diseases; and IHC and molecular pathology products, including primary antibodies and detection kits for use in hospitals, and reference and research laboratories. The company also provides VP, multiplex IHC, and supernova antibodies; chromogens, fluorescence, multiplex, and mach detection products; and instrumentation, such as decloaking chambers, kinetic slide stainers, desert chamber pros, nemesis, and imaging systems. In addition, it offers decalcification, antigen ret...
60 Berry Drive
Pacheco, CA 94553
Founded in 1997
Key Executives for Biocare Medical, LLC
Co-Founder, CEO & President
Co-Founder, Co-Owner, CFO, COO & Executive VP
Chief Scientific Officer and VP of Research & Develoopment
Director of Research and Development
Compensation as of Fiscal Year 2017.
Biocare Medical, LLC Key Developments
Morphotek, Inc. Announces License Agreement with Biocare Medical, LLC to Develop, Commercialize Diagnostic Kit for Detection of Mesothelin in Malignant Tissues
Dec 16 15
Morphotek Inc. announced that it entered into a second collaboration and license agreement with Biocare Medical, LLC (Biocare) to develop and commercialize an immunohistochemical (IHC) diagnostic kit utilizing Morphotek's proprietary monoclonal antibody to specifically detect mesothelin with Biocare's intelliPATH Automated Stainer. The agreement provides Biocare with a worldwide non-exclusive license to develop, manufacture and commercialize an IHC kit for detection of mesothelin on formalin-fixed paraffin-embedded (FFPE) tumor tissues. This is the second such agreement between Morphotek and Biocare; the first a license agreement signed in 2011 to develop kits, now commercially available, to detect folate receptor alpha in malignant tissues. Mesothelin is a cell-surface protein that is over-expressed in a variety of cancers including mesothelioma, non-small cell lung adenocarcinoma, pancreatic and ovarian carcinoma. Studies have found its expression variable among different cancer types; therefore, diagnostic assays that can identify patients with mesothelin-positive cancers may enable better diagnosis and treatment options for patients affected with mesothelin-expressing cancers. Mesothelin is the target of Morphotek's investigational therapeutic candidate, amatuximab, which is currently being assessed in a randomized, double-blind clinical trial in patients with newly diagnosed malignant pleural mesothelioma.
Similar Private Companies By Industry
Recent Private Companies Transactions
August 25, 2017
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries